CYP19A1 and cancer: Among the pain conditions reported in cancer survivors in direct relation to long-term cancer treatment, one notes chemotherapy-induced peripheral neuropathy (30% prevalence), aromatase inhibitor-associated musculoskeletal syndrome (up to 50% prevalence) and rheumatic pain associated with checkpoint inhibitors (up to 22% prevalence) [8].